Jump to content

Biocon

From Wikipedia, the free encyclopedia
(Redirected from Clinigene)

Biocon Limited
Company typePublic
BSE: 532523
NSE: BIOCON
ISININE376G01013
IndustryBiopharmaceutical
Founded1978 (46 years ago) (1978)
FounderKiran Mazumdar-Shaw
Headquarters
Bangalore, Karnataka
,
India
Key people
  • Kiran Mazumdar-Shaw
    (Executive Chairperson)
  • Peter Bains
    (Group CEO)
  • Siddharth Mittal
    (CEO & Managing Director)
  • Shreehas P Tambe
    (CEO & Managing Director, Biocon Biologics Limited)
Products
  • Biologics
  • Small molecules
  • Branded formulations
  • Research services
RevenueIncrease ₹15,621 crore (US$1.9 billion) (FY24)[1]
Increase ₹4,195 crore (US$500 million) (FY24)[1]
Increase ₹1,030 crore (US$120 million) (FY24)[1]
Total assetsIncrease ₹52,044 crore (US$6.2 billion) (2023)[2]
Total equityIncrease ₹22,489 crore (US$2.7 billion) (2023)[2]
Number of employees
16,545 (March 2023)[3]
Subsidiaries
  • Biocon Biologics
  • Syngene International
Websitewww.biocon.com

Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978.[4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries,[5] including the United States and Europe.[4] It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.[6]

Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab) and KRABEVA (Bevacizumab).[4]

Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in the contract research and development organization.[4]

History

[edit]

Biocon was founded in 1978 with US$10,000 as the initial capital by a Kiran Mazumdar who was born to Gujarati parents in Bangalore.[7][8]

In 1979, Biocon Became the first Indian company to manufacture and export enzymes to the US and Europe.[9]

In 1989, Unilever acquired Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International; Biocon receives US funding for proprietary technologies.[10]

In 1994, Biocon established Syngene International as a Custom Research Company (CRC).[10]

During 1998, Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity.[11]

In 2001, Biocon became the first Indian company to be approved by USFDA for the manufacture of lovastatin; PlaFractor is granted a US 2001 and worldwide patent.[12]

In 2003, Biocon becomes the first company worldwide to develop human insulin on a Pichia expression system.[13]

During 2006 BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for head-and-neck cancer is launched and APJ Abdul Kalam inaugurates India's Largest Biotech-Hub "Biocon Park".[14]

In 2008, Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH.[15]

During 2009 Syngene-Bristol Myers Squibb research facility is established in Bengaluru.[16]

Later during 2009 Mylan announced strategic collaboration with Biocon to Enter the Global Generic Biologics Market.[17]

In 2010, Biocon expanded to Malaysia, biopharmaceutical manufacturing and R&D facility established in Iskandar Malaysia, Johor.[18]

In 2012,Abbott announces collaboration with Syngene to Open First Nutrition R&D Center in India.[19]

During 2013 Biocon launched biologic drug ALZUMAb to treat psoriasis.[20]

During 2014 Biocon launched the first biosimilar drug CANMAb to treat breast cancer.[21]

In 2015, Biocon launched hepatitis-C drug in India under brand name CIMIVIR-L.[22]

In 2016, Biocon Became the first Indian company to launch a biosimilar Insulin Glargine pen in Japan.[23]

During 2016, Syngene set up Amgen R&D center in Bangalore.[24]

In 2017, Biocon's Insugen became the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.[25]

In 2017, USFDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin.[26]

During 2018, Biocon, Mylan get European Commission approval to market biosimilar insulin glargine.[27]

During 2021 Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together.[28] Another aspect of the deal involves Bicocon selling 15% of its biologics subsidiary to Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.[28]

During 2022, Biocon Biologics bought the biosimilar assets of Viatris, for $3.34 billion.[29]

Corporate governance

[edit]
Kiran Mazumdar-Shaw is an Indian entrepreneur. She founded Biocon in 1978.

Biocon's CMD Kiran Mazumdar–Shaw joined Biocon in 1978.[30][31][32]

Her efforts in biotechnology have drawn global recognition both for the industry in India and for Biocon and was called India's "biotech queen" by The Economist[33] and India's "mother of invention" by The New York Times.[34] She was named among Time magazine's 2010 100 most influential people in the world based not only on her contribution to the biotech industry but also because she gives back to the community.[35] Shaw features on the Forbes list of "The World's 100 Most Powerful Women"[36] and in the Financial Times "Top 50 Women in Business" list.[37]

Shaw is the recipient of several awards including the Nikkei Asia Prize, 2009 for Regional Growth,[38] Express Pharmaceutical Leadership Summit Award 2009 for Dynamic Entrepreneur, The Economic Times 'Businesswoman of the Year', the 'Veuve Clicquot Initiative For Economic Development For Asia, Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, 'Technology Pioneer' recognition by World Economic Forum and the Indian Chamber of Commerce Lifetime Achievement Award. She has received two Indian national awards—Padma Shri (1989) and Padma Bhushan (2005) for her pioneering efforts in Industrial Biotechnology.[30]

Biocon announced that Christiane Hamacher has been appointed as the CEO of Biocon Biologic India Limited, with her term having started in March 2019.[39]

On 3 December 2019, Siddharth Mittal took over from Arun Chandavarkar who retired as CEO & Joint Managing Director of Biocon.[40]

In 2021, Christiane Hamacher resigned from her position, following differences with Kiran Mazumdar-Shaw.[41]

Subsidiaries

[edit]

Biocon Biologics

[edit]
Inside Biocon Research Centre in Biocon Park, Bommasandra, Bangalore.

Biocon Biologics is Biocon's biosimilar subsidiary. In 2021 Biocon and Viatris received approval to launch Semglee, an insulin glargine-yfgn injection, which is the first interchangble biosimilar for diabetes in the United States.[42] In 2021, Biocon sold 15% of Biocon Biologics to Serum Institute of India for a valuation of $4.9 billion, for which Biocon will receive access to 100 million doses of vaccines per annum for 15 years.[43] These vaccines will mainly be supplied from Serum Institute's upcoming vaccine facility in Pune, and Biocon will also have the commercialization rights of Serum Institute's vaccine portfolio, which includes the COVID-19 vaccine, for the international markets.[43] In May 2022, Viatris sold its biosimilars division to Biocon Biologics for a price of US$3.335 billion.[44]

Syngene International Ltd

[edit]

Established in 1993, Syngene International Limited is a contract research and development organization (CDMO). In the CDMO space, Syngene primarily focuses on research innovation and manufacturing services for their clients.[45] The company has four divisions: drug discovery services, dedicated research centres, development devices and manufacturing.[45] Syngene works with eight of the top 10 global pharma companies and, Syngene's clients include Amgen, Zoetis, GlaxoSmithKline and Bristol Myers Squibb.[46] Syngene has been expanding its operations. Since 2020, he company has opened an R&D centre in Hyderabad, is building an API manufacturing facility in Mangalore, which is scheduled to be commissioned in 2022, and has expanded their R&D facility in Bangalore.[47] Syngene also provides biologics CDMO services.[48] In July 2022, Syngene signed a 10-year agreement with Zoetis to manufacture the drug substance for Librela (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs.[49] SynVent is Syngene's drug discovery and development platform for both small and large molecules.[50] In September 2022, Biocon divested 5.4% of its shares in Syngene International.[51]

Clinigene

[edit]

Clinigene International Limited is a subsidiary on Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.[30]

BBPL

[edit]

Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.[30]

Biocon-AxiCorp

[edit]

In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company.[52]

NeoBiocon

[edit]

Incorporated in January 2008, NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in Abu Dhabi.[53]

Biofusion Therapeutics Limited

[edit]

Incorporated in March 2021, 100% owned by Biocon.[54]

Strategic partnerships

[edit]

Biocon and Amylin

[edit]

In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin provides expertise in peptide hormone development, particularly in the area of phybrid technology and metabolic disease therapeutics. Biocon will utilise its expertise in recombinant microbial expression and experience in preclinical and clinical development of diabetes products to manufacture the compound.[30]

Biocon and IATRICa

[edit]

In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies are co-developing candidate products based upon IATRICa's technology platform and Biocon's expertise in drug development, biologics manufacturing, and clinical research. The goal of this collaboration is to develop a therapeutic vaccine where the T cell-mediated immunity is enhanced and maintained against a tumor that otherwise evades immune responses. Methods of developing, characterising and scaling up of conjugated monoclonal antibody production are being currently studied.[30]

Biocon and Viatris

[edit]

In 2009, Biocon signed a collaboration agreement with Viatris to develop and commercialize generic biologics. Viatris and Biocon will share development, capital, and other costs to bring products to market. Viatris will have exclusive commercialisation rights in the USA, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries through a profit-sharing arrangement with Biocon.[30]

Biocon and Optimer

[edit]

Biocon and Optimer Pharmaceuticals, a biopharmaceutical company focused on the treatment of serious infections such as Clostridioides difficile infection (CDI), have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient, fidaxomicin.[4][30]

Biocon and Vaccinex

[edit]

Biocon is also developing fully human antibodies BVX 10 and BVX-20 with a US antibody technology partner, Vaccinex. The partnership was initiated in 2004. BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients with rheumatoid arthritis. Biocon's strategic partnership with Vaccinex allows access to their proprietary human antibody platform technology, thereby providing a strong IP protection to Biocon's antibody pipeline.[4][30]

Biocon and Abraxis

[edit]

In 2007, Biocon and Abraxis BioScience, Inc. entered into an agreement that helped Biocon out-license the rights to develop and market a biosimilar version of GCSF (Granulocyte Colony-Stimulating Factor) to North American and European markets.[30]

Biocon and Sandoz

[edit]

In January 2018, Sandoz (a Novartis division) announced a global partnership with Biocon to develop, manufacture, and commercialize multiple biosimilars in immunology and oncology for patients worldwide.[55]

Operations

[edit]

Biocon's manufacturing facilities are located at two sites in Bangalore.[30]

Biocon's R&D focuses on the entire drug development pathway – from process development to non-clinical and clinical research.[30]

Biocon offers 36 brands of products across the four therapeutic divisions of diabetology, nephrology, oncology, and cardiology.[4]

References

[edit]
  1. ^ a b c "Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr". Biocon. 16 May 2024. Retrieved 17 May 2024.
  2. ^ a b "Biocon Consolidated Balance Sheet, Biocon Financial Statement & Accounts". www.moneycontrol.com. Retrieved 31 July 2020.
  3. ^ "Biocon Annual Report 2017" (PDF). Biocon.
  4. ^ a b c d e f g "Biocon Annual Report, 2010" (PDF). Archived from the original (PDF) on 26 October 2010. Retrieved 20 September 2010.
  5. ^ "Active Pharmaceutical Ingredient (API)". Biocon. 3 July 2020. Retrieved 26 December 2022.
  6. ^ Plum-Mörschel, Leona; Singh, Gursharan; Murugesan, Sundara Moorthi Nainar; Marwah, Ashwani; Panda, Jayanti; Loganathan, Subramanian; Athalye, Sandeep N. (2022). "Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US -licensed Humulin® R formulation in healthy subjects: Results from the RHINE -1 ( Recombinant Human INsulin Equivalence-1 ) study". Diabetes, Obesity and Metabolism. 24 (4): 713–721. doi:10.1111/dom.14635. ISSN 1462-8902. PMC 9303355. PMID 34981621.
  7. ^ Egan, Mary Ellen. "Big Shot in Bangalore". Forbes. Retrieved 7 March 2021.
  8. ^ Katyal, Surabhi (15 June 2015). "6 Indian and Indian Origin Women in the list of Forbes 100 Most Powerful Women in the World". The Better India. Retrieved 21 September 2024.
  9. ^ nimmi. "Biocon, India's largest biotech company". www.indianmirror.com. Retrieved 8 February 2018.
  10. ^ a b Kiran Mazumdar-Shaw, CMD, Biocon Ltd, 'Biotech Is Not for Punters', Outlook Money, 15 July 2004
  11. ^ Baisya, Rajat K. (9 September 2010). Winning Strategies for Business. SAGE Publications India. ISBN 9788132106081.
  12. ^ Pearce (2009). Strategic Management 10E. McGraw-Hill Education (India) Pvt Limited. ISBN 9780070264380.
  13. ^ "Biocon Ltd: About Biocon Pharma Company Founder, CEO, Products & Contact Address". www.brandindiapharma.in. Retrieved 8 February 2018.
  14. ^ "Dr. APJ Abdul Kalam Dedicates India\'s First Cancer Drug BIOMab EGFR to the Nation and Inaugurates India\'s Largest Biotech-Hub "Biocon Park" | Evaluate". www.evaluategroup.com. Retrieved 8 February 2018.
  15. ^ "Biocon Acquires 70% Stake in German Pharmaceutical Company, AxiCorp: Biosimilars Will be Main Focus | Evaluate". www.evaluategroup.com. Retrieved 8 February 2018.
  16. ^ Burns, Lawton R. (13 January 2014). India's Healthcare Industry: Innovation in Delivery, Financing, and Manufacturing. Cambridge University Press. ISBN 9781107044371.
  17. ^ "Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market". MediaRoom. Retrieved 8 February 2018.
  18. ^ "Biocon Limited To Build US$161 Million R&D Facility in Bio-XCell, Malaysia". Asian Scientist Magazine | Science, technology and medical news updates from Asia. 11 September 2011. Retrieved 8 February 2018.
  19. ^ Abbott. "Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India". prnewswire.com (Press release). Retrieved 8 February 2018.
  20. ^ "Biocon unveils biologic drug to treat skin disorder". @businessline. Retrieved 8 February 2018.
  21. ^ "Kiran Mazumdar-Shaw's Biocon develops new breast cancer drug". The Times of India. 18 January 2014. Retrieved 19 January 2014.
  22. ^ Pilla, Viswanath (24 December 2015). "Biocon launches hepatitis-C drug in India". livemint.com/. Retrieved 8 February 2018.
  23. ^ Pilla, Viswanath (15 July 2016). "Biocon's partner FUJIFILM launches insulin glargine in Japan". livemint.com/. Retrieved 20 December 2017.
  24. ^ "Indian CRO Syngene sets up Amgen R&D center in Bangalore | FierceBiotech". www.fiercebiotech.com. 6 September 2016. Retrieved 8 February 2018.
  25. ^ "Biocon Wins MYR 300 Million Contract For Insulin From MoH Malaysia". www.biosimilardevelopment.com. Retrieved 20 December 2017.
  26. ^ Trivedi, Isha (2 December 2017). "US FDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin". livemint.com/. Retrieved 8 February 2018.
  27. ^ "Biocon, Mylan get European Commission approval to market biosimilar insulin glargine". Business Medical Dialogues. 30 March 2018.
  28. ^ a b Das, Sohini (17 September 2021). "Biocon Biologics, Serum Institute Life Sciences enter strategic alliance". Business Standard India. Retrieved 23 March 2022.
  29. ^ Rajagopal, Divya (1 March 2022). "Biocon's unit buys biosimilar assets of Viatris for $3.34 billion". mint. Retrieved 22 March 2022.
  30. ^ a b c d e f g h i j k l Biocon Website ("Biocon - Biosimilars, Fermentation, Oral Insulin, Human Insulin, Immunosuppresants, Monoclonal Antibody, Recombinant Proteins, Biopharmaceutical, Biotechnology Company, EGFR, GCSF, Fermentation, Orlistat, Insulin Glargine, Insulin Lispro, Peptides, Insulin Aspart". Archived from the original on 7 August 2014. Retrieved 3 August 2014.)
  31. ^ Nature Reviews Drug Discovery, July 2010
  32. ^ Biospectrum India Friday, 11 July 2008
  33. ^ Kiran Mazumdar Shaw, India's fermentation queen, 30 August 2001
  34. ^ "How India's Mother of Invention Built an Industry", 16 August 2003
  35. ^ Time, 29 April 2010
  36. ^ The World's 100 Most Powerful Women, Forbes, 19 August 2009
  37. ^ FT top 50 women in world business, Financial Times, 25 September 2009
  38. ^ The Hindu, 12 May 2009
  39. ^ "Biocon appoints Christiane Hamacher as CEO of Biocon Biologics India". Medical Dialogues. 2 March 2019.
  40. ^ "Biocon names Siddharth Mittal as new CEO, Joint MD; bids farewell to Arun Chandavarkar". Medical Dialogues. 3 December 2019.
  41. ^ "Christiane Hamacher quits as CEO of Biocon Biologics". BusinessLine. 22 January 2021. Retrieved 21 September 2024.
  42. ^ "Press Release titled "Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes"" (PDF). Biocon.com. 2021. Retrieved 22 March 2022.
  43. ^ a b Biocon (16 September 2021). "Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance". Biocon. Retrieved 23 April 2022.
  44. ^ Li, Robert (2 March 2022). "Viatris sells biosimilars unit for USD 3.335 billion". ICLG. Retrieved 31 March 2022.
  45. ^ a b Babu, Venkatesha (2021). "We are co-innovating with global pharma companies: Syngene MD & CEO". www.thehindubusinessline.com. Retrieved 15 March 2022.
  46. ^ Ghosh, Debojyoti (2021). "Syngene's winning formula". www.fortuneindia.com. Retrieved 15 March 2022.
  47. ^ Rughani, Kushal (10 February 2021). "Initiating Coverage: Syngene International Ltd" (PDF). HDFC Securities. p. 2. Retrieved 22 April 2022.
  48. ^ Khandekar, Siddhant; Thakur, Raunak (21 January 2022). "Syngene International (SYNINT)" (PDF). ICICI Direct. p. 2. Retrieved 17 May 2022.
  49. ^ Rautela, Isha (14 July 2022). "Syngene inks 10-year biologics manufacturing pact with Zoetis". www.thehindubusinessline.com. Retrieved 17 July 2022.
  50. ^ "SynVent Integrated Drug Discovery". Syngene International. Retrieved 24 July 2022.
  51. ^ Jaiswar, Pooja Sitaram (6 September 2022). "Biocon divests over ₹1,220 crore stake in Syngene International in bulk deal". mint. Retrieved 8 September 2022.
  52. ^ "Atlas Copco sells majority stake in rental business". Pump Industry Analyst. 2006 (10): 12. 29 October 2006. doi:10.1016/s1359-6128(06)71621-4. ISSN 1359-6128.
  53. ^ "Building on a Foundation of IP". www.wipo.int. Retrieved 20 March 2023.
  54. ^ "Biocon incorporates wholly-owned subsidiary Biofusion Therapeutics". flipit.money. Retrieved 20 March 2023.
  55. ^ "Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars | Novartis". Novartis. Retrieved 8 February 2018.
Wikimedia Commons has media related to Biocon.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Biocon&oldid=1258908053"